Am I Catching a Falling Knife?

Align Technology (ALGN) just fell off#stockanalysis a cliff—down 32.90% in ten days, and we’re breaking down why. In this episode of "Am I Catching a Falling Knife?", Dave unpacks ALGN’s brutal earnings report, forecasts a 36% hit to quarterly profits, and reveals three bold buy-levels you won’t want to miss.💸 Is this an elite business on sale or a value trap wrapped in orthodontic vene...

The digital payments giant PayPal ($PYPL) is under pressure. Despite solid earnings and raised guidance, market fears about competition and declining engagement are crushing the stock price. In this episode of ‘Am I Catching a Falling Knife?’, host Dave slices through the noise with sharp analysis, a clean DCF breakdown, and valuation insights that could help you decide: is PayPal a comeback story...

📉 UPS has taken a sharp tumble—down 8.73%, missing profits, and holding back full-year guidance... again. But is this just macro panic, or a golden entry point for long-term investors? In this episode of *Am I Catching a Falling Knife?*, we break down UPS's core business, analyze their earnings miss, and run the numbers—from DCF to PEG—to find potential buy zones. Is $76.16 fair value, or is...

Welcome to Am I Catching a Falling Knife?, your weekly dose of brutally honest market breakdowns. 📉 This episode: Spotify (SPOT) takes a 12.73% plunge—strong user growth, but profits? Not so strong. We dissect their earnings miss, currency headwinds, and those pesky social charges that dragged the stock down. 🔔 Subscribe for sharp takes on trending stocks and market narratives. 📢 Disclaimer: Th...

Novo Nordisk (NVO) is down 20% — but is this a golden buying opportunity or a financial free fall in disguise? Plus: custom buy zones for value hunters. If you're watching this stock... don’t make a move until you've seen this analysis. Not financial advice. Just brutal clarity.🔔 Subscribe for more breakdowns of falling knives, rising opportunities, and everything in between.

Centene Corporation (CNC) just took a brutal hit – but is it a golden opportunity or a classic "falling knife"? In this episode of *Am I Catching a Falling Knife?*, we dissect CNC’s Q2 earnings, rising medical cost fears, and a lawsuit that’s gutting investor confidence. This isn’t financial advice – it’s fearless finance entertainment. Subscribe for sharp takes and deeper dives every we...

Duolingo (NASDAQ: DUOL) just took a 10% dive — and we’re here to unpack what’s really going on. Is slowing user engagement about to slash earnings? In this episode of *“Am I Catching a Falling Knife?”*, host Dave breaks down Duolingo’s revenue model, margins, and market expectations ahead of Q2 2025 earnings. With analyst downgrades and valuation models suggesting potential downside, could DUOL be...

Southwest Airlines (LUV) just dropped 12%—but is Wall Street overreacting? In this episode of Am I Catching a Falling Knife?, we dissect the turbulence: missed earnings, bag fee backlash, and a surprise $2B buyback. Is LUV a turnaround story or a warning sign?👉 Subscribe for more high-stakes market deep dives. 🔔 Turn on notifications so you never miss the next knife drop.🧠 This isn’t financial...

Welcome to Am I Catching a Falling Knife?, where we dig into plummeting stocks to uncover hidden value—or devastating traps. This week, Dave breaks down Charter Communications (CHTR), which nosedived 22% after a rough Q2 earnings call. Was it just subscriber loss panic... or is this the beginning of the end?📉 What triggered the sell-off 📊 Earnings impact and valuation fallout 💰 Custom buy zones...

Abbott Laboratories (ABT) just dropped its guidance — is this a short-term stumble or a long-term opportunity? In this episode of Am I Catching a Falling Knife?, host Dave breaks down Abbott's Q2 earnings surprise, the real impact of fading COVID-19 testing demand, and why China diagnostics might be dragging down this healthcare heavyweight. 💉📉We analyze the numbers, run a DCF valuation, and...

UnitedHealth Group (UNH) has taken a nosedive, and we're slicing into the reasons: DOJ heat on Medicare billing practices and spiking medical costs. Is this healthcare titan a rebound candidate or a bloody mess? 🩸In this episode of *Am I Catching a Falling Knife?*, Dave breaks down the numbers behind UNH’s tumble, from revenue impact to DCF analysis. Are we buying the dip , or waiting for the...

Honeywell (HON) just Crashed—even after beating earnings and raising guidance. What gives? In this episode of *Am I Catching a Falling Knife?*, Dave breaks down exactly why investors are spooked. Contracting operating margins, declining free cash flow, and a new corporate strategy are shaking up the market's confidence. Is this a warning sign... or a golden buy-the-dip moment? We unpack the na...

Chipotle Mexican Grill (CMG) just served up a seriously sour Q2 earnings report—missing revenue expectations and slashing guidance. In this episode of Am I Catching a Falling Knife?, Dave breaks down the 4% drop in comparable sales, the brutal impact of negative operating leverage, and whether the burrito king’s fair value just got shredded. Is this a moment for value investors to bite… or is Wall...

Enphase Energy just dropped 15%. Is this a buying opportunity—or a brutal earnings trap? In this episode of Am I Catching a Falling Knife?, host Dave breaks down: 🔍 The solar market squeeze 📉 Projected -30% earnings impact 💰 ENPH's narrative-adjusted fair value With deep-dive analysis, custom buy levels, and a clear breakdown of what's driving the plunge, this is the video every ENPH in...

TXN stock just took a dive, but is it a disaster or a discount? 🤔 In this episode of Am I Catching a Falling Knife?, host Dave unpacks the chaos around Texas Instruments' Q3 guidance, global trade tensions, and a potential –7% earnings hit.🔍 What you’ll learn:Why tariffs and China exposure are spooking investors 🌏How TXN's analog empire might be wobbling ⚙️Narrative-driven valuation: Fa...

GM stock has dropped over 6% in just ten days—and the story behind it is far bigger than a dip. In this episode of Am I Catching a Falling Knife?, Dave breaks down the shocking $1.1B tariff hit General Motors took in Q2 and the projected $4–5B impact for 2025. Using a step-by-step earnings impact analysis and a discounted cash flow valuation, we reveal GM's true fair value—and whether now’s th...